Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.35 -5.3%	$7.30	$5.90 ▼ $30.31	$566.41M	2.17	1.50 million shs	1.54 million shs
ATAI atai Life Sciences	$3.23 +15.8%	$2.30	$1.03 ▼ $3.35	$558.94M	1.44	2.18 million shs	14.88 million shs
LYEL Lyell Immunopharma	$9.24 -2.9%	$9.30	$7.65 ▼ $34.90	$140.97M	-0.24	72,271 shs	24,175 shs
TYRA Tyra Biosciences	$10.39 -4.3%	$9.89	$6.42 ▼ $29.60	$576.56M	1.07	291,903 shs	104,279 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-5.28%	-5.65%	-1.61%	-14.53%	-76.43%
ATAI atai Life Sciences	+15.77%	+23.28%	+38.63%	+119.73%	+101.88%
LYEL Lyell Immunopharma	-2.94%	-5.23%	-3.55%	+6.55%	-73.75%
TYRA Tyra Biosciences	-4.33%	+1.27%	+9.37%	+16.48%	-48.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.8933 of 5 stars	4.3	4.0	1.8	2.5	1.3
ATAI atai Life Sciences	3.1998 of 5 stars	3.8	4.0	2.3	1.7	0.6
LYEL Lyell Immunopharma	3.0934 of 5 stars	2.8	5.0	0.9	3.3	1.3
TYRA Tyra Biosciences	3.1272 of 5 stars	3.5	5.0	1.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$20.29	176.05% Upside
ATAI atai Life Sciences	3.50	Strong Buy	$9.00	178.64% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	62.34% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	196.76% Upside

Current Analyst Ratings Breakdown

Latest LYEL, ARVN, TYRA, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.04	N/A	N/A	$8.17 per share	0.90
ATAI atai Life Sciences	$310K	2,087.41	N/A	N/A	$0.69 per share	4.68
LYEL Lyell Immunopharma	$60K	2,280.74	N/A	N/A	$26.21 per share	0.35
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	7/29/2025 (Estimated)
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$25.00	N/A	N/A	N/A	-514,649.22%	-73.66%	-60.99%	8/6/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)

Latest LYEL, ARVN, TYRA, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	LYEL Lyell Immunopharma	-$0.19	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$3.80	-$3.60	+$0.20	-$0.18	N/A	$0.01 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	4.58	4.58
ATAI atai Life Sciences	0.08	4.07	4.07
LYEL Lyell Immunopharma	N/A	7.49	7.49
TYRA Tyra Biosciences	N/A	22.78	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
ATAI atai Life Sciences	28.41%
LYEL Lyell Immunopharma	66.05%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
ATAI atai Life Sciences	26.80%
LYEL Lyell Immunopharma	22.30%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
LYEL Lyell Immunopharma	270	14.81 million	11.51 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable

LYEL, ARVN, TYRA, and ATAI Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Trading Up 5.7% - Should You Buy?

July 16 at 1:00 PM | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?

July 15, 2025 | marketbeat.com

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Morningstar

July 9, 2025 | morningstar.comM

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

July 8, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?

July 3, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

July 2, 2025 | targetedonc.comT

Tyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancer

July 1, 2025 | pharmabiz.comP

Tyra Biosciences' (TYRA) "Buy" Rating Reiterated at HC Wainwright

July 1, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Rating of "Buy" by Brokerages

July 1, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

June 30, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Here's What Happened

June 23, 2025 | marketbeat.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of Stock

June 21, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in Stock

June 20, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

June 17, 2025 | insidertrades.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%

May 6, 2025 | aaii.comA

Tyra Biosciences price target lowered to $28 from $29 at BofA

March 30, 2025 | markets.businessinsider.com

Tyra Biosciences reports Q4 EPS (43c) vs. (53c) last year

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, ARVN, TYRA, and ATAI Company Descriptions

Arvinas NASDAQ:ARVN

$7.35 -0.41 (-5.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.40 +0.05 (+0.68%)

As of 07/18/2025 06:11 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

atai Life Sciences NASDAQ:ATAI

$3.23 +0.44 (+15.77%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.32 +0.09 (+2.79%)

As of 07/18/2025 07:59 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Lyell Immunopharma NASDAQ:LYEL

$9.24 -0.28 (-2.94%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$9.56 +0.32 (+3.46%)

As of 07/18/2025 04:58 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Tyra Biosciences NASDAQ:TYRA

$10.39 -0.47 (-4.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$10.20 -0.19 (-1.82%)

As of 07/18/2025 06:11 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time